Related Experiment Videos
High-dose infusion therapy for severe depressions
Pharmacopsychiatry
|March 1, 1988
Summary
High-dose intravenous dibenzepine shows antidepressant effects comparable to electroconvulsive therapy (ECT) in treating endogenous depression. This novel parenteral administration may bypass hepatic metabolism, offering a different therapeutic profile for depressive states.
Area of Science:
- Psychiatry
- Clinical Pharmacology
- Neurobiology
Background:
- Oral antidepressants undergo extensive hepatic metabolism.
- Parenteral administration may alter drug pharmacokinetics and pharmacodynamics.
- Endogenous depression requires effective treatment options.
Purpose of the Study:
- To investigate the efficacy and biochemical effects of high-dose intravenous dibenzepine.
- To compare intravenous dibenzepine with oral antidepressants and electroconvulsive therapy (ECT).
- To explore the potential of parenteral administration to circumvent hepatic metabolism.
Main Methods:
- High-dose intravenous administration of dibenzepine.
- Comparative analysis using dexamethasone suppression tests (DSTs).
- Monitoring of prolactin (PRL) responses and Fischer Symptom Check List (FSCL) scores.
Main Results:
- Intravenous dibenzepine demonstrated comparable symptom regression to ECT in endogenous depression.
- Biochemical changes observed suggest a distinct action compared to orally administered drugs.
- Differences noted in DSTs, PRL responses, and FSCL scores support a unique pharmacokinetic profile.
Conclusions:
- High-dose intravenous dibenzepine offers a promising alternative for endogenous depression, potentially equivalent to ECT.
- Parenteral administration may provide a therapeutic advantage by altering drug metabolism.
- Further research is warranted to elucidate the full clinical potential of this administration route.